Results 111 to 120 of about 47,203 (289)

Toll‐Like Receptor 4 Signaling in Natural N‐Acylethanolamines and Derivative NAE‐Like Compounds: Mechanisms and Implications for Neuroimmune and Inflammatory Processes in a Systematic Search Approach

Phytotherapy Research, EarlyView.
ABSTRACT N‐acylethanolamines (NAEs) are endogenous fatty acid amides structurally related to the endocannabinoid anandamide and function as bioactive lipid mediators with broad regulatory roles in inflammation and neuroinflammation. Among pattern‐recognition receptors, Toll‐like receptor 4 (TLR4) occupies a central position in innate immune ...
Damiana Scuteri, Francesca Guida, Giacinto Bagetta, Sabatino Maione, Maria Tiziana Corasaniti, Morena Zusso   +5 more
wiley   +1 more source

Forensic challenges in a case of suspected filicide, matricide, and post‐mortem dismemberment

Journal of Forensic Sciences, EarlyView.
Abstract Familicide represents one of the most complex forms of domestic violence in forensic practice. Among intrafamilial homicides, filicide and matricide pose major medico‐legal and criminological challenges, particularly when autopsy findings are nonspecific or severely altered by post‐mortem changes.
Isabella Caristo, Rosario Barranco, Giulio Fraternali Orcioni, Domenico Coviello, Francesco Ventura   +4 more
wiley   +1 more source

Pharmacokinetics of Cannabinoids

Pain Research and Management, 2005
Delta‐9‐tetrahydrocannabinol (Δ‐9‐THC) is the main psychoactive ingredient of cannabis (marijuana). The present review focuses on the pharmacokinetics of THC, but also includes known information for cannabinol and cannabidiol, as well as the synthetic marketed cannabinoids, dronabinol (synthetic THC) and nabilone.
openaire   +3 more sources

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Critical appraisal of the potential use of cannabinoids in cancer management

, 2013
Belinda J Cridge, Rhonda J Rosengren Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand Abstract: Cannabinoids have been attracting a great deal of interest as potential anticancer agents.
Cridge BJ, Rosengren RJ
core  

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

The psychometric properties of validated tools to assess cannabis use disorder: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Aims To systematically review the evidence on the psychometric performance and accuracy of screening or diagnostic tools for cannabis use disorder. Method Systematic review and meta‐analysis which included studies conducted in clinical settings, schools, universities, community settings and population‐based surveys in multiple countries and ...
Janni Leung, Daniel Stjepanovic, Stephanie Fong, Danielle Dawson, Giang Vu, Tesfa Yimer, Caitlin McClure‐Thomas, Wayne Denis Hall, Gary Chung Kai Chan   +8 more
wiley   +1 more source

Approved indications for Cannabinoids [PDF]

Review of all FDA and EMA approved indications of cannabinoids for medicinal ...
Darkovska-Serafimovska, Marija
core   +2 more sources